Shares of Fresenius SE & Co. KGaA (OTCMKTS:FSNUY – Get Rating) have earned an average recommendation of “Hold” from the twelve analysts that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, five have given a hold recommendation and six have given a buy recommendation to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $50.55.
FSNUY has been the subject of a number of research analyst reports. Berenberg Bank upped their price objective on shares of Fresenius SE & Co. KGaA from €55.95 ($60.16) to €60.25 ($64.78) and gave the company a “buy” rating in a research report on Wednesday, February 16th. Deutsche Bank Aktiengesellschaft cut their price objective on shares of Fresenius SE & Co. KGaA from €38.00 ($40.86) to €36.00 ($38.71) and set a “hold” rating for the company in a research report on Friday, February 25th. JPMorgan Chase & Co. cut their price objective on shares of Fresenius SE & Co. KGaA from €42.30 ($45.48) to €34.50 ($37.10) and set a “neutral” rating for the company in a research report on Thursday, February 24th. Zacks Investment Research lowered shares of Fresenius SE & Co. KGaA from a “hold” rating to a “sell” rating in a research report on Friday, February 4th. Finally, Credit Suisse Group cut their price objective on shares of Fresenius SE & Co. KGaA from €43.00 ($46.24) to €35.00 ($37.63) and set a “neutral” rating for the company in a research report on Monday, February 28th.
Shares of FSNUY opened at $9.41 on Wednesday. The company has a 50-day simple moving average of $9.14 and a 200-day simple moving average of $10.09. The firm has a market capitalization of $21.02 billion, a P/E ratio of 9.70 and a beta of 1.31. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.85 and a current ratio of 1.13. Fresenius SE & Co. KGaA has a 52 week low of $7.37 and a 52 week high of $14.81.
Fresenius SE & Co KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.
- Get a free copy of the StockNews.com research report on Fresenius SE & Co. KGaA (FSNUY)
- Does PNC Financial Stock Belong in Your Portfolio?
- Institutional Buying Puts A Bottom In Manpower Group Inc
- Workhorse Johnson & Johnson Plows New All-Time Highs
- Fastenal Stock is Ready to Sprint Higher
- J.B. Hunt Transportation Services Fires On All Cylinders
Receive News & Ratings for Fresenius SE & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.